270 related articles for article (PubMed ID: 29057200)
1. Cannabis Withdrawal: A Review of Neurobiological Mechanisms and Sex Differences.
Schlienz NJ; Budney AJ; Lee DC; Vandrey R
Curr Addict Rep; 2017 Jun; 4(2):75-81. PubMed ID: 29057200
[TBL] [Abstract][Full Text] [Related]
2. Brain imaging of cannabinoid type I (CB
Spindle TR; Kuwabara H; Eversole A; Nandi A; Vandrey R; Antoine DG; Umbricht A; Guarda AS; Wong DF; Weerts EM
Addict Biol; 2021 Nov; 26(6):e13061. PubMed ID: 34028926
[TBL] [Abstract][Full Text] [Related]
3. Sex differences in endocannabinoid tone in a pilot study of cannabis use disorder and acute cannabis abstinence.
Martin EL; Baker NL; Sempio C; Christians U; Klawitter J; McRae-Clark AL
Addict Biol; 2023 Oct; 28(10):e13337. PubMed ID: 37753564
[TBL] [Abstract][Full Text] [Related]
4. Cannabis use, abuse, and withdrawal: Cannabinergic mechanisms, clinical, and preclinical findings.
Kesner AJ; Lovinger DM
J Neurochem; 2021 Jun; 157(5):1674-1696. PubMed ID: 33891706
[TBL] [Abstract][Full Text] [Related]
5. The endocannabinoid system as a target for the treatment of cannabis dependence.
Clapper JR; Mangieri RA; Piomelli D
Neuropharmacology; 2009; 56 Suppl 1(Suppl 1):235-43. PubMed ID: 18691603
[TBL] [Abstract][Full Text] [Related]
6. Cannabis reinforcement and dependence: role of the cannabinoid CB1 receptor.
Cooper ZD; Haney M
Addict Biol; 2008 Jun; 13(2):188-95. PubMed ID: 18279497
[TBL] [Abstract][Full Text] [Related]
7. Inhibitors of endocannabinoid-metabolizing enzymes reduce precipitated withdrawal responses in THC-dependent mice.
Schlosburg JE; Carlson BL; Ramesh D; Abdullah RA; Long JZ; Cravatt BF; Lichtman AH
AAPS J; 2009 Jun; 11(2):342-52. PubMed ID: 19430909
[TBL] [Abstract][Full Text] [Related]
8. The cannabis withdrawal syndrome.
Budney AJ; Hughes JR
Curr Opin Psychiatry; 2006 May; 19(3):233-8. PubMed ID: 16612207
[TBL] [Abstract][Full Text] [Related]
9. Impact of cyclooxygenase-2 inhibition on cannabis withdrawal and circulating endocannabinoids in daily cannabis smokers.
Haney M; Bedi G; Cooper ZD; Herrmann ES; Reed SC; Foltin RW; Kingsley PJ; Marnett LJ; Patel S
Addict Biol; 2022 Jul; 27(4):e13183. PubMed ID: 35754107
[TBL] [Abstract][Full Text] [Related]
10. The Endocannabinoid System Modulating Levels of Consciousness, Emotions and Likely Dream Contents.
Murillo-Rodriguez E; Pastrana-Trejo JC; Salas-Crisóstomo M; de-la-Cruz M
CNS Neurol Disord Drug Targets; 2017; 16(4):370-379. PubMed ID: 28240187
[TBL] [Abstract][Full Text] [Related]
11. Cannabis alters epigenetic integrity and endocannabinoid signalling in the human follicular niche.
Fuchs Weizman N; Wyse BA; Szaraz P; Defer M; Jahangiri S; Librach CL
Hum Reprod; 2021 Jun; 36(7):1922-1931. PubMed ID: 33954787
[TBL] [Abstract][Full Text] [Related]
12. Efficacy and safety of a fatty acid amide hydrolase inhibitor (PF-04457845) in the treatment of cannabis withdrawal and dependence in men: a double-blind, placebo-controlled, parallel group, phase 2a single-site randomised controlled trial.
D'Souza DC; Cortes-Briones J; Creatura G; Bluez G; Thurnauer H; Deaso E; Bielen K; Surti T; Radhakrishnan R; Gupta A; Gupta S; Cahill J; Sherif MA; Makriyannis A; Morgan PT; Ranganathan M; Skosnik PD
Lancet Psychiatry; 2019 Jan; 6(1):35-45. PubMed ID: 30528676
[TBL] [Abstract][Full Text] [Related]
13. Assessment of Withdrawal, Mood, and Sleep Inventories After Monitored 3-Week Abstinence in Cannabis-Using Adolescents and Young Adults.
Sullivan RM; Wallace AL; Stinson EA; Montoto KV; Kaiver CM; Wade NE; Lisdahl KM
Cannabis Cannabinoid Res; 2022 Oct; 7(5):690-699. PubMed ID: 34678051
[No Abstract] [Full Text] [Related]
14. CB
Trexler KR; Eckard ML; Kinsey SG
Pharmacol Biochem Behav; 2019 Feb; 177():27-33. PubMed ID: 30597181
[TBL] [Abstract][Full Text] [Related]
15. Cannabis and cannabinoids: pharmacology and rationale for clinical use.
Pertwee RG
Forsch Komplementarmed; 1999 Oct; 6 Suppl 3():12-5. PubMed ID: 10575283
[TBL] [Abstract][Full Text] [Related]
16. Actions of delta-9-tetrahydrocannabinol in cannabis: relation to use, abuse, dependence.
Cooper ZD; Haney M
Int Rev Psychiatry; 2009 Apr; 21(2):104-12. PubMed ID: 19367504
[TBL] [Abstract][Full Text] [Related]
17. Blockade of endocannabinoid hydrolytic enzymes attenuates precipitated opioid withdrawal symptoms in mice.
Ramesh D; Ross GR; Schlosburg JE; Owens RA; Abdullah RA; Kinsey SG; Long JZ; Nomura DK; Sim-Selley LJ; Cravatt BF; Akbarali HI; Lichtman AH
J Pharmacol Exp Ther; 2011 Oct; 339(1):173-85. PubMed ID: 21719468
[TBL] [Abstract][Full Text] [Related]
18. The cannabis withdrawal syndrome: current insights.
Bonnet U; Preuss UW
Subst Abuse Rehabil; 2017; 8():9-37. PubMed ID: 28490916
[TBL] [Abstract][Full Text] [Related]
19. Role of cannabis and endocannabinoids in the genesis of schizophrenia.
Fernandez-Espejo E; Viveros MP; Núñez L; Ellenbroek BA; Rodriguez de Fonseca F
Psychopharmacology (Berl); 2009 Nov; 206(4):531-49. PubMed ID: 19629449
[TBL] [Abstract][Full Text] [Related]
20. A Systematic Review of the Efficacy of Cannabinoid Agonist Replacement Therapy for Cannabis Withdrawal Symptoms.
Werneck MA; Kortas GT; de Andrade AG; Castaldelli-Maia JM
CNS Drugs; 2018 Dec; 32(12):1113-1129. PubMed ID: 30361897
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
